Trial Profile

Relative Bioavailability of Tebipenem (SPR994) Crushed Tablet Formulation Administered by Nasogastric Tube in Healthy Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 01 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tebipenem pivoxil (Primary)
Indications Haemophilus infections; Pyelonephritis; Shigella infections; Streptococcal infections; Urinary tract infections
Focus Pharmacokinetics

Most Recent Events

26 Feb 2024 Status changed from active, no longer recruiting to completed.
14 Nov 2022 Results assessing the relative bioavailability of crushed tebipenem tablets administered via nasogastric tube (NGT) with or without concomitant enteral feeds, published in the Journal of Antimicrobial Chemotherapy.
26 Aug 2022 Planned End Date changed from 1 Sep 2022 to 1 Oct 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com